Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
Jean‐Christophe Pignon(Brigham and Women's Hospital), Sabina Signoretti(Brigham and Women's Hospital), Toni K. Choueiri(Harvard University), Michael B. Atkins(Georgetown University), Rebecca B. Jennings(Brigham and Women's Hospital), Paul J. Catalano(Computational Physics (United States)), David A. Braun(Yale Cancer Center), Gordon J. Freeman(Dana-Farber Cancer Institute), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Opeyemi A. Jegede(Dana-Farber Cancer Institute), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Christine E. Horak(Bristol-Myers Squibb (United States)), David F. McDermott(Beth Israel Deaconess Medical Center), Yuko Ishii(Bristol-Myers Squibb (United States)), Aguirre De Cubas(Vanderbilt University)
Cited by 10
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k